Green light for BioFoam

CryoLife, a US human tissue processing and bio-surgical device company, is set to receive funding to develop BioFoam, a protein hydrogel adhesive that can treat gunshot and mortar wounds.

CryoLife, a human tissue processing and bio-surgical device company, announced yesterday that the US Senate and the US House of Representatives have passed the 2005 Defence Appropriations Conference Report which included $1 million for the development of BioFoam.

BioFoam is a protein hydrogel adhesive that is in the pre-clinical stage of development. BioFoam contains an expansion agent and sets quickly while expanding, providing an opportunity to rapidly arrest bleeding of large vessel injuries and sealing the wound.

BioFoam is based on the same technology as BioGlue, a CryoLife product approved by the US Food and Drug Administration to control bleeding as an adjunct to sutures and staples for use in open surgical repair of large vessels.

“BioFoam is being developed for use in battlefield situations to treat gunshot and mortar wounds, which will allow more time for soldiers to reach a medical facility,” said Congressman Phil Gingrey.

Steven G. Anderson, CryoLife President and Chief Executive Officer added, “We believe this funding for the development and potential use of BioFoam may save the lives of US soldiers serving our country in the armed forces.”

On the web